MRUS - Pambiji Buku Bisnis merus.nl

The price history of Merus N.V. (MRUS) demonstrates the dynamics of an asset currently valued at 0.77. The company's financial performance relies on the development of cutting-edge antibodies and the receipt of licensing payments. Simultaneously, Merus N.V. (MRUS) adheres to waste disposal environmental standards and bioethics. Despite its narrow specialization in oncology, the company minimizes risks through partnerships with pharmaceutical behemoths.

MRUS Kapitalisasi Buku Merus Corp (04.07.2022 - 10.01.2026)

Rincian metrik keuangan lan pasar Merus (MRUS)

- rega lan prakiraan konsensus rega:

Rega saham Merus Therapeutics|MRUS - Bagan rega target

- data kapitalisasi pasar:

Kapitalisasi pasar Merus NV|MRUS - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi saben Saham Merus|MRUS - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku merus.nl|MRUS - Aset Agregat Perusahaan

- data utang lan likuiditas:

Rasio Utang marang Ekuitas Merus N.V.|MRUS - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Merus NV|MRUS - Gunggung utang perusahaan|Utang-utang marang nilai buku Merus NV

Ringkesan analisis perusahaan:Merus Therapeutics - MRUS

Book value capitalization reflects the difference between total assets and liabilities, demonstrating the real value of equity over time. For Merus N.V. (MRUS), the history of book value capitalization clearly captures the inflow of funds from secondary offerings, which provide the liquidity necessary to complete antibody clinical trials, allowing investors to assess the stability of the company's fundamental base against high regulatory risks.

Pesaing Merus N.V.